Skip to main content

Cartesian Therapeutics, Inc.

RNAC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001453687

No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Cartesian Therapeutics, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of RNAC: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders7266−6
Shares6.58M6.40M−182.9K (−2.8%)
Value$86.7M$66.5M−$20.2M (−23.3%)

New holders (8)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to RNAC in Q2 2025
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc41,317$429.3K0.00%
Renaissance Technologies LLC19,500$202.6K0.00%
Alliancebernstein L.P.11,895$123.6K0.00%
Miller Financial Services LLC11,643$121.0K0.15%
Alerus Financial NA1,000$10.4K0.00%
Russell Investments Group, Ltd.55$5710.00%
Allworth Financial LP15$1560.00%
Essential Partners LLC15$1560.00%

Sold out (14)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.